Overexpression of apolipoprotein E3 in transgenic. Rabbits causes combined hyperlipidemia by stimulating hepatic VLDL production and impairing VLDL lipolysis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 12, 1999, Pages 2952-2959

  Huang, Yadong ^a,c   Ji, Zhong Sheng ^a   Brecht, Walter J ^a   Rall Jr , Stanley C ^a   Taylor, John M ^a   Mahley, Robert W ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

Author keywords

ApoB; Hypertriglyceridemia; Lipoprotein lipase; VLDL clearance

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN E3; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; APOLIPOPROTEIN E; LIPOPROTEIN; LIPOPROTEIN CHOLESTEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; HYPERLIPIDEMIA; LIPID METABOLISM; LIPOLYSIS; LIPOPROTEIN METABOLISM; NONHUMAN; PRIORITY JOURNAL; RABBIT; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BIOSYNTHESIS; BLOOD; GENE EXPRESSION; GENETICS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IN VITRO STUDY; LIVER; METABOLISM; PHYSIOLOGY; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; APOLIPOPROTEIN E3; APOLIPOPROTEINS E; CHOLESTEROL; CHOLESTEROL, VLDL; GENE EXPRESSION; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPOLYSIS; LIPOPROTEINS; LIVER; RABBITS;

EID: 0033238035     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.12.2952     Document Type: Article

References (39)

1. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622-630.
2. Mahley RW, Rall SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York, NY: McGraw-Hill; 1995:1953-1980.
3. Mahley RW, Ji Z-S, Brecht WJ, Miranda RD, He D. Role of heparan sulfate proteoglycans and the LDL receptor-related protein in remnant lipoprotein metabolism. Ann N Y Acad Sci. 1994;737:39-52.
4. Mahley RW, Ji Z-S. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res. 1999;40:1-16.
5. Rall SC Jr, Mahley RW. The role of apolipoprotein E genetic variants in lipoprotein disorders. J Intern Med. 1992;231:653-659.
6. Salah D, Bohnet K, Gueguen R, Siest G, Visvikis S. Combined effects of lipoprotein lipase and apolipoprotein E polymorphisms on lipid and lipoprotein levels in the Stanislas cohort. J Lipid Res. 1997;38:904-912.
7. Cohn JS, Tremblay M, Amiot M, Bouthillier D, Roy M, Genest J Jr, Davignon J. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. Arterioscler Thromb Vasc Biol. 1996;16:149-159.
8. Huang Y, Liu XQ, Rall SC Jr, Taylor JM, von Eckardstein A, Assmann G, Mahley RW. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J Biol Chem. 1998;273:26388-26393.
9. Fan J, Ji Z-S, Huang Y, de Silva H, Sanan D, Mahley RW, Innerarity TL, Taylor JM. Increased expression of apolipoprotein E in transgenic rabbits results in reduced levels of very low density lipoproteins and an accumulation of low density lipoproteins in plasma. J Clin Invest. 1998;101: 2151-2164.
10. Huang Y, Schwendner SW, Rall SC Jr, Sanan DA, Mahley RW. Apolipoprotein E2 transgenic rabbits: modulation of the type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis. J Biol Chem. 1997;272:22685-22694.
11. Huang Y, Schwendner SW, Rall SC Jr, Mahley RW. Hypolipidemic and hyperlipidemic phenotypes in transgenic mice expressing human apolipoprotein E2. J Biol Chem. 1996;271:29146-29151.
12. Huang Y, Rall SC Jr, Mahley RW. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2. Arterioscler Thromb Vasc Biol. 1997;17: 2817-2824.
13. de Silva HV, Más-Oliva J, Taylor JM, Mahley RW. Identification of apolipoprotein B-100 low density lipoproteins, apolipoprotein B-48 remnants, and apolipoprotein E-rich high density lipoproteins in the mouse. J Lipid Res. 1994;35:1297-1310.
14. Aalto-Setälä K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN, Breslow JL. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice: diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest. 1992;90:1889-1900.
15. Kuipers F, Jong MC, Lin Y, van Eck M, Havinga R, Bloks V, Verkade HJ, Hofker MH, Moshage H, van Berkel TJC, Vonk RJ, Havekes LM. Impaired secretion of very low density lipoprotein-triglycerides by apolipoprotein E-deficient mouse hepatocytes. J Clin Invest. 1997;100: 2915-2922.
16. Connelly PW, Maguire GF, Vezina C, Hegele RA, Kuksis A. Kinetics of lipolysis of very low density lipoproteins by lipoprotein lipase: importance of particle number and noncompetitive inhibition by particles with low triglyceride content. J Biol Chem. 1994;269:20554-20560.
17. Huang Y, Liu XQ, Rall SC Jr, Mahley RW. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins. J Biol Chem. 1998;273:17483-17490.
18. Bilheimer DW, Eisenberg S, Levy RI. The metabolism of very low density lipoprotein proteins. I: preliminary in vitro and in vivo observations. Biochim Biophys Acta. 1972;260:212-221.
19. Hussain MM, Mahley RW, Boyles JK, Lindquist PA, Brecht WJ, Innerarity TL. Chylomicron metabolism: chylomicron uptake by bone marrow in different animal species. J Biol Chem. 1989;264:17931-17938.
20. Ji Z-S, Sanan DA, Mahley RW. Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans. J Lipid Res. 1995;36:583-592.
21. Ji Z-S, Fazio S, Mahley RW. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J Biol Chem. 1994;269:13421-13428.
22. Rensen PCN, van Berkel TJC. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions m vitro and in vivo. J Biol Chem. 1996;271:14791-14799.
23. Jong MC, Dahlmans VEH, Hofker MH, Havekes LM. Nascent very-low-density lipoprotein triacylglycerol hydrolysis by lipoprotein lipase is inhibited by apolipoprotein E in a dose-dependent manner. Biochem J. 1997;328:745-750.
24. Jong MC, Dahlmans VEH, van Gorp PJJ, Breuer ML, Mol MJTM, van der Zee A, Frants RR, Hofker MH, Havekes LM. Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C1. Arterioscler Thromb Vasc Biol. 1996;16:934-940.
25. Hospattankar AV, Fairwell T, Ronan R, Brewer HB Jr. Amino acid sequence of human plasma apolipoprotein C-II from normal and hyperlipoproteinemic subjects. J Biol Chem. 1984;259:318-322.
26. Woollett LA, Osono Y, Herz J, Dietschy JM. Apolipoprotein E competitively inhibits receptor-dependent low density lipoprotein uptake by the liver but has no effect on cholesterol absorption or synthesis in the mouse. Proc Natl Acad Sci U S A. 1995;92:12500-12504.
27. Borén J, Rustaeus S, Olofsson S-O. Studies on the assembly of apolipoprotein B-100- and B-48-containing very low density lipoproteins in McA-RH7777 cells. J Biol Chem. 1994;269:25879-25888.
28. McLeod RS, Zhao Y, Selby SL, Westerlund J, Yao Z. Carboxyl-terminal truncation impairs lipid recruitment by apolipoprotein B100 but does not affect secretion of the truncated apolipoprotein B-containing lipoproteins. J Biol Chem. 1994;269:2852-2862.
29. Wu X, Shang A, Jiang H, Ginsberg HN. Low rates of apoB secretion from HepG2 cells result from reduced delivery of newly synthesized triglyceride to a "secretion-coupled" pool. J Lipid Res. 1996;37:1198-1206.
30. Hamilton RL, Wong JS, Guo LSS, Krisans S, Havel RJ. Apolipoprotein E localization in rat hepatocytes by immunogold labeling of cryothin sections. J Lipid Res. 1990;31:1589-1603.
31. Fazio S, Yao Z. The enhanced association of apolipoprotein E with apolipoprotein B-containing lipoproteins in serum-stimulated hepatocytes occurs intracellularly. Arterioscler Thromb Vasc Biol. 1995;15:593-600.
32. Elovson J, Huang YO, Baker N, Kannan R. Apolipoprotein B is structurally and metabolically heterogeneous in the rat. Proc Natl Acad Sci U S A. 1981;78:157-161.
33. Greeve J, Altkemper I, Dieterich J-H, Greten H, Windler E. Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J Lipid Res. 1993;34:1367-1383.
34. Chait A, Albers JJ, Brunzell JD. Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia. Eur J Clin Invest. 1980;10:17-22.
35. Janus ED, Nicoll AM, Turner PR, Magill P, Lewis B. Kinetic bases of the primary hyperlipidaemias: studies of apolipoprotein B turnover in genetically defined subjects. Eur J Clin Invest. 1980;10:161-172.
36. Brunzell JD, Sniderman AD, Albers JJ, Kwiterovich PO Jr. Apoproteins B, and A-I, and coronary artery disease in humans. Arteriosclerosis. 1984;4:79-83.
37. Venkatesan S, Cullen P, Pacy P, Halliday D, Scott J. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb. 1993;13: 1110-1118.
38. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease, II: genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544-1568.
39. Grundy SM, Chait A, Brunzell JD. Familial combined hyperlipidemia workshop. Arteriosclerosis. 1987;7:203-207.